Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...

Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat ...

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement ...

Americas Gold And Silver Announces New Major Discoveries In Idaho And Mexico And A Strong 2025 Resource & Reserve Update ...

According to David A. Ricks, chair and CEO of Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing “fewer than 1 in 10 people who could benefit ...

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Phase 1 Part 3 Trial of DA-1726 to ...

The Drug Payment Scheme (DPS) caps the maximum a family pays for prescribed approved medication at 80 Euro per month. Major ...

Americas Gold and Silver is pleased to announce that its consolidated silver Measured and Indicated Mineral Resources has ...

The CBSE Class 12 Biology exam held on March 27, 2026, was widely described as moderate, familiar, and student-friendly.